Skip to content

Study · Animal study (in vivo) · rat · 1990

3 results

Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.

Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally AV

Endocrinology1 Dec 1990Cited by 46 (Europe PMC)

PMID2174343 (opens in a new tab)DOI10.1210/endo-127-6-3052 (opens in a new tab)PepBankPUB-02174343
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rat Dunning prostate tumors, triptorelin treatment down-regulated membrane LHRH receptors compared with untreated animals.

    In plain wordsIn rats, triptorelin reduced prostate tumor LHRH receptors compared with untreated animals.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseTumor membrane LHRH receptors
    Study

    ratn: not reported in source

    Dunning R3327 prostate tumors and anterior pituitaries
    Comparator
    Untreated animals
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Treatment with D-Trp6-LHRH produced down-regulation of membrane receptors for LHRH in Dunning tumors.
    2 context sentences
    Summary · context
    Membrane receptors for LHRH were evaluated in Dunning R3327 prostate cancers and rat anterior pituitaries.
    Summary · context
    The receptors were characterized both in untreated animals and after in vivo treatment with microcapsules of the agonist D-Trp6-LHRH and a sustained delivery system releasing different doses (23.8, 47.6, 71.4 micrograms/day) of LHRH antagonist [Ac-D-Nal(2)1-D-Phe(4Cl)2-D-Pal(3)3,D-Cit6, D-Ala10]-LHRH (SB-75).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats, prolonged triptorelin microcapsule treatment reduced pituitary LHRH receptor Bmax compared with untreated animals.

    In plain wordsIn rats, triptorelin microcapsules reduced pituitary LHRH receptor binding capacity compared with untreated animals.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePituitary receptor Bmax
    Study

    ratn: not reported in source

    Dunning R3327 prostate tumors and anterior pituitaries
    Comparator
    Untreated animals
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Prolonged treatment with microcapsules of D-Trp6-LHRH reduced both Bmax and Kd.
    3 context sentences
    Summary · context
    Analysis of the binding data showed that interaction of labeled D-Trp6-LHRH with binding sites in anterior pituitaries was consistent with the presence of a single class of noncooperative receptors (Kd = 43.75 x 10(-9) M; Bmax = 5.25 pmol/mg membrane proteins).
    Summary · context
    Membrane receptors for LHRH were evaluated in Dunning R3327 prostate cancers and rat anterior pituitaries.
    Summary · context
    The receptors were characterized both in untreated animals and after in vivo treatment with microcapsules of the agonist D-Trp6-LHRH and a sustained delivery system releasing different doses (23.8, 47.6, 71.4 micrograms/day) of LHRH antagonist [Ac-D-Nal(2)1-D-Phe(4Cl)2-D-Pal(3)3,D-Cit6, D-Ala10]-LHRH (SB-75).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, prolonged triptorelin microcapsule treatment reduced pituitary LHRH receptor Kd compared with untreated animals.

    In plain wordsIn rats, triptorelin microcapsules reduced the pituitary LHRH receptor dissociation constant compared with untreated animals.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePituitary receptor Kd
    Study

    ratn: not reported in source

    Dunning R3327 prostate tumors and anterior pituitaries
    Comparator
    Untreated animals
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Prolonged treatment with microcapsules of D-Trp6-LHRH reduced both Bmax and Kd.
    3 context sentences
    Summary · context
    Analysis of the binding data showed that interaction of labeled D-Trp6-LHRH with binding sites in anterior pituitaries was consistent with the presence of a single class of noncooperative receptors (Kd = 43.75 x 10(-9) M; Bmax = 5.25 pmol/mg membrane proteins).
    Summary · context
    Membrane receptors for LHRH were evaluated in Dunning R3327 prostate cancers and rat anterior pituitaries.
    Summary · context
    The receptors were characterized both in untreated animals and after in vivo treatment with microcapsules of the agonist D-Trp6-LHRH and a sustained delivery system releasing different doses (23.8, 47.6, 71.4 micrograms/day) of LHRH antagonist [Ac-D-Nal(2)1-D-Phe(4Cl)2-D-Pal(3)3,D-Cit6, D-Ala10]-LHRH (SB-75).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.